S&P Futures
4,574.50 -1.25 (-0.03%) Dow Futures
34,654.00 +32.00 (+0.09%) Nasdaq Futures
15,972.00 -16.50 (-0.10%) Russell 2000 Futures
2,198.60 -6.60 (-0.30%) Crude Oil
67.72 +1.22 (+1.83%) Gold
1,772.50 +11.80 (+0.67%)
Agile Therapeutics, Inc. (AGRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.6366 |
| Open | 0.6350 |
| Bid | 0.6051 x 1100 |
| Ask | 0.6300 x 800 |
| Day's Range | 0.5700 - 0.6399 |
| 52 Week Range | 0.5400 - 3.7700 |
| Volume | |
| Avg. Volume | 2,013,463 |
| Market Cap | 52.958M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6990 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- TipRanks
These 2 Penny Stocks Are Set for Massive Gains, Says Oppenheimer
What kind of stocks stir up controversy like no other? Penny stocks. These tickers trading for less than $5 per share have earned a reputation as some of the most divisive names on Wall Street, with these plays either met with open arms or given the cold shoulder. It’s understandable why some investors are wary. Those opposed are quick to point out that there could be a very real reason these stocks are changing hands for pocket change, with the low share prices often masking obstacles like weak
- Zacks
Agile Therapeutics (AGRX) Reports Q3 Loss, Lags Revenue Estimates
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 5.26% and -13.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Agile Therapeutics Reports Third Quarter 2021 Financial Results
Prescription Demand Growth Continues in the Third Quarter 2021 with a 61% Increase in Twirla Cycles Dispensed Twirla Refill Rates Continue to Grow by 86% in Third Quarter 2021 Company Advances Programs Focused on Increasing Demand for Twirla Management to Host Conference Call Today, Tuesday, November 2, 2021 at 4:30 p.m. EDT PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three mont
